- Home
- Uncategorized
- Pfizer Tops Leaderboard Across ...
Pfizer is popular among doctors. This is the conclusion that can be drawn from the results of a poll that included 160 medical professionals and concluded that Big Pharma is regarded as a leader across three out of five therapeutic fields and is acknowledged for its creative advertising.
ZoomRx recently released research in which doctors’ opinions on pharma companies’ performance across many criteria in five different therapeutic fields were analyzed. Pfizer came out on top of the competition in all three categories—cardiovascular, vaccines, and oncology. Pfizer almost had a clean sweep in all five therapeutic categories – only AbbVie in immunology and Biogen in neurology stood in the way.
A Deeper Look Into the Oncology Stats Where Pfizer Leads
- Pfizer is doing things correctly, as seen by a deeper inspection of the cancer statistics.
- The company was placed in first place in oncology, tied with AstraZeneca; more than half of the respondents (53%) cited the company as an authority in oncology.
- Big Pharma placed some distance between itself and its competitors on other criteria, with 60% of medical professionals recognizing it as the most reliable source of new cancer marketing.
- With a score of 50% on the innovative ad measure, AstraZeneca placed in second place.
Despite this, there are still areas in cancer where Pfizer can make improvements in the oncology field. The firm came in third on the list of best-in-class salespeople and medical science liaison (MSL) engagements, following AstraZeneca and Merck & Co. on both lists. The $12 billion cancer franchise that the company has established (PDF) around Ibrance came in third place.
Sales representatives and medical science liaisons working for Pfizer performed better in other therapeutic areas. When it comes to vaccinations, Pfizer came out on top of the sales rep leaderboard, and on the scale of MSL encounters, they finished in second place behind GSK. Pfizer led the way in terms of inventive advertisements in the area of vaccines, where it was joint first with GSK, as well as in cardiovascular illness.
Overall, firms that physicians regarded as being leaders in a particular therapeutic field fared well on the majority of the criteria that were evaluated. These metrics included sales rep relationships, MSL interactions, innovative advertising, and others. One major exception to this rule is Sanofi in the field of vaccines. Half of the doctors questioned acknowledged Sanofi as a leader in the vaccine industry, tying it with Merck for second place behind Pfizer; nonetheless, only a few of the polled physicians had positive things to say about the French pharmaceutical.
On several of the other parameters, Sanofi achieved a ranking of fifth or sixth. 23% of physicians described Sanofi as a business possessing a portfolio of innovative vaccines. They placed Sanofi in a tie for fifth place with BioNTech and ahead of Janssen by a few percentage points. BioNTech and J&J are two smaller companies in the field, although they are well-known for the COVID-19 injections that they produce. Sanofi, on the other hand, provides vaccinations against a wide variety of illnesses.
